Cargando…

Efficacy and safety of apatinib in patients with untreated or chemotherapy-refractory soft tissue sarcoma: a multicenter, phase 2 trial

BACKGROUND: Anti-angiogenic agents have been reported to exert promising clinical activity for advanced soft tissue sarcoma (STS). Apatinib, a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, is effective and safe for various solid tumors, but its role in STS remains unclear....

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Wenxi, Zhang, Hongmei, Chen, Jing, Zhang, Xing, Chen, Yong, Qu, Guofan, Huang, Gang, Zhou, Yuhong, Ye, Ting, Fan, Zhengfu, Yao, Yang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9577792/ https://www.ncbi.nlm.nih.gov/pubmed/36267741 http://dx.doi.org/10.21037/atm-22-4229

Ejemplares similares

Efficacy and safety of apatinib in advanced refractory soft tissue sarcoma and association with histologic subtypes: a multicenter retrospective study
por: Wang, Xiangling, et al.
Publicado: (2022)

Advanced alveolar soft part sarcoma responds to apatinib
por: Zhou, Yong, et al.
Publicado: (2017)

Assessment of Efficiency and Safety of Apatinib in Advanced Bone and Soft Tissue Sarcomas: A Systematic Review and Meta-Analysis
por: Long, Zuoyao, et al.
Publicado: (2021)

Apatinib as targeted therapy for sarcoma
por: Li, Feng, et al.
Publicado: (2018)

Clinical study of apatinib in the treatment of stage IV osteogenic sarcoma after failure of chemotherapy
por: Liao, Zhichao, et al.
Publicado: (2020)

Retrospective review of the activity and safety of apatinib and anlotinib in patients with advanced osteosarcoma and soft tissue sarcoma
por: Tian, Zhichao, et al.
Publicado: (2020)

Phase II trial of VEGFR2 inhibitor apatinib for metastatic sarcoma: focus on efficacy and safety
por: Liao, Zhichao, et al.
Publicado: (2019)

Treatment of uterine high-grade endometrial stromal sarcoma with apatinib combined with chemotherapy: A case report
por: Zhang, Ying, et al.
Publicado: (2019)

A Study Of Efficacy And Safety With Apatinib Or Apatinib Combined With Chemotherapy In Recurrent/advanced Ovarian Cancer Patients
por: Yang, Mi, et al.
Publicado: (2019)

The efficacy and safety of apatinib in metastatic alveolar soft part sarcoma: a case series of six patients in one institution
por: Wang, Yitian, et al.
Publicado: (2019)

Efficacy and Safety of Apatinib in the Treatment of Chemotherapy-Refractory Metastatic Colorectal Cancer: A Systematic Review
por: Khan, Aujala Irfan, et al.
Publicado: (2022)

Safety and efficacy of combination therapy with apatinib and doxorubicin in metastatic soft tissue sarcomas: an observational study from multiple institutions
por: Tian, Zhichao, et al.
Publicado: (2019)

Efficacy and safety of Apatinib in stage IV sarcomas: experience of a major sarcoma center in China
por: Li, Feng, et al.
Publicado: (2017)

A pilot study of multi-antigen stimulated cell therapy-I plus camrelizumab and apatinib in patients with advanced bone and soft-tissue sarcomas
por: Zhou, Yan, et al.
Publicado: (2023)

Safety and efficacy of apatinib combined with iodine-125 in chemotherapy-refractory advanced lung cancer: A case report
por: Zhang, Yunchao, et al.
Publicado: (2020)

Efficacy and Safety of Apatinib in Patients with Recurrent or Refractory Melanoma
por: Yuan, Shumin, et al.
Publicado: (2022)

The efficacy and safety of apatinib for refractory malignancies: a review and meta-analysis
por: Sun, Dantong, et al.
Publicado: (2018)

Apatinib with doxorubicin and ifosfamide as neoadjuvant therapy for high-risk soft tissue sarcomas: a retrospective cohort study
por: Tian, Zhichao, et al.
Publicado: (2021)

Correction to: Efficacy and Safety of Apatinib in Patients with Recurrent or Refractory Melanoma
Publicado: (2022)

Feasibility of Apatinib in Radioiodine-Refractory Differentiated Thyroid Carcinoma
por: Du, Wei, et al.
Publicado: (2022)

Antitumor activity and safety of camrelizumab combined with apatinib in patients with relapsed or refractory peripheral T-cell lymphoma: An open-label, multicenter, phase II study
por: Liu, Yanfei, et al.
Publicado: (2023)

The efficacy and safety of apatinib in metastatic alveolar soft part sarcoma: a case series of six patients in one institution [Corrigendum]
Publicado: (2019)

The use of apatinib in treating primary pleural synovial sarcoma: A case report
por: Chen, Sumei, et al.
Publicado: (2019)

Cost-Effectiveness of Apatinib and Cabozantinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer
por: Shi, Bo, et al.
Publicado: (2022)

Combination of apatinib mesylate and second-line chemotherapy for treating gastroesophageal junction adenocarcinoma
por: Lu, Bin, et al.
Publicado: (2019)

Influence of KDR Genetic Variation on the Efficacy and Safety of Patients with Chemotherapy Refractory Metastatic CRC Who Received Apatinib Treatment
por: Bai, Ming, et al.
Publicado: (2021)

A Phase II Study of Apatinib in Patients with Chemotherapy‐Refractory Esophageal Squamous Cell Carcinoma (ESO‐Shanghai 11)
por: Chu, Li, et al.
Publicado: (2021)

Successful treatment with apatinib for refractory recurrent malignant gliomas: a case series
por: Zhang, Honghong, et al.
Publicado: (2017)

Low-Dose Apatinib Combined With S-1 in Refractory Metastatic Colorectal Cancer: A Phase 2, Multicenter, Single-Arm, Prospective Study
por: Li, Ning, et al.
Publicado: (2021)

Low-dose apatinib monotherapy in advanced chemotherapy-refractory small cell lung cancer: a case series and literature review
por: Liu, Ying-ying, et al.
Publicado: (2019)

Apatinib Monotherapy for Chemotherapy-Refractory Metastatic Colorectal Cancer: A Multi-centre, Single-Arm, Prospective Study
por: Wang, Fen, et al.
Publicado: (2020)

A Phase II Study of Flavopiridol in Patients With Previously Untreated Advanced Soft Tissue Sarcoma
por: Morris, Don G., et al.
Publicado: (2006)

The efficacy and safety of apatinib in Ewing’s sarcoma: a retrospective analysis in one institution
por: Wang, Yitian, et al.
Publicado: (2018)

Recombined humanized endostatin (Endostar) combined with chemotherapy for advanced bone and soft tissue sarcomas in stage IV
por: Xing, Peipei, et al.
Publicado: (2016)

Real-world experience with pembrolizumab in patients with advanced soft tissue sarcoma
por: Liu, Jiayong, et al.
Publicado: (2021)

The Efficacy and Safety of Apatinib in Refractory/Relapse Advanced Pediatric Solid Tumor: A Retrospective Study
por: Sun, Feifei, et al.
Publicado: (2020)

Duration of untreated bipolar disorder: a multicenter study
por: Zhang, Ling, et al.
Publicado: (2017)

Efficacy and toxicity of apatinib combined with or without chemotherapy for patients with advanced or metastatic chemotherapy-refractory gastric adenocarcinoma: A prospective clinical study
por: Guo, Yesong, et al.
Publicado: (2019)

AZGP1 inhibits soft tissue sarcoma cells invasion and migration
por: Liu, Jiayong, et al.
Publicado: (2018)

Radiation Therapy for Chemotherapy Refractory Gingival Myeloid Sarcoma
por: Lee, Daniel Y., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_23p9c6abuurvpfpr6t860tn17m